Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

Danese S.;Vermeire S.;Zhou W.;Pangan A. L.;Siffledeen J.;Greenbloom S.;Hebuterne X.;D'Haens G.;Nakase H.;Panes J.;Higgins P. D. R.;Juillerat P.;Lindsay J. O.;Loftus E. V.;Sandborn W. J.;Reinisch W.;Chen M. -H.;Sanchez Gonzalez Y.;Huang B.;Xie W.;Liu J.;Weinreich M. A.;Panaccione R.

2022-01-01